GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT01726517
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
- Conditions
- Interventions
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01721109
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸University of South Florida - Department of Pediatrics, Tampa, Florida, United States
🇺🇸East Bay AIDS Center Medical Group, Oakland, California, United States
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT01713283
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT01707472
- Locations
- 🇺🇸
NIH Department of Laboratory Medicine, Bethesda, Maryland, United States
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 583
- Registration Number
- NCT01705574
- Locations
- 🇺🇸
Mercer University Mercer Medicine, Macon, Georgia, United States
🇺🇸Saint Michael's Medical Center, Newark, New Jersey, United States
🇺🇸New Jersey Medical School, Newark, New Jersey, United States
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 39
- Registration Number
- NCT01705847
- Locations
- 🇳🇱
VU Medical Center (VUmc), Amsterdam, Netherlands
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇳🇱St. Antonius Hospital, Nieuwegein, Netherlands
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 870
- Registration Number
- NCT01701401
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT01687257
Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT01687270
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 421
- Registration Number
- NCT01682720
- Locations
- 🇩🇪
Centrum fuer interdisziplinaere Medizin Muenster GmbH, Münster, Germany
🇩🇪Universitatsklinikum, Hamburg, Germany
🇦🇹Wilhelminenspital, Wien, Austria